Ritlecitinib and brepocitinib showed significant benefits over placebo at 8 weeks of the 32-week, phase 2b, VIBRATO trial in moderate to severe active ulcerative colitis.
This question was addressed in at the Ludwig Maximilian University Clinic for Psychiatry and Psychotherapy, in the context of the global Mental Health Week.
In moderately to severely active ulcerative colitis patients, symptoms control was reached significantly more for upadacitinib over placebo patients after 2 weeks.
Dupilumab showed maintained patient benefits for eosinophilic oesophagitis. The 28-week phase 3 trial showed sustained symptomatic, histologic, and endoscopic benefits.
The administration of ZED-1227 demonstrated clinical and histological efficacy in coeliac disease, a first effective therapy for these patients in a phase 2a trial.
Maintained efficacy of tofacitinib was observed for a substantial proportion of ulcerative colitis (UC) patients in the OCTAVE open-label extension study.
Interview with Dr. Giuliano Piccoliori, physician in South Tyrol and scientific head of the Institute of General Medicine and Public Health in Bolzano on the current situation and future of general medicine.
In a real-life setting, motorised spiral enteroscopy (MSE) was safe and effective to use in a large cohort of patients. Safety and feasibility was demonstrated.
Endoscopists of varying experience reliably excluded submucosal invasion in large non-pedunculated colorectal polyps using a novel clinical decision support tool.
Corticosteroid-free remission was reached in more patients receiving filgotinib in the maintenance phase than placebo for moderately to severely active UC.
Patients with IBS treated with anti-TNFα showed a reduced immune response to COVID-19 mRNA vaccines compared to IBD patients without anti-TNFα treatment and healthy controls.
Conference Chair and APAAACI President Prof. Ruby Pawankar talks about the highlights of this year's APAAACI Conference. Prof. Pawankar shares her thoughts about allergy prevention, the challenges of the global pandemic and the impact of her research on the next generation.
Subcutaneous and sublingual immunotherapy (SCIT, SLIT) are the most common methods for controlling allergic rhinitis (AR). At this year's APAAACI Congress, Prof. M. Okano, MD, presented research on the safety, efficacy and adherence of the two treatment regimens.
Superiority of upadacitinib over placebo as induction therapy for patients with moderately to severely active ulcerative colitis was observed.
Since the first anaphylactic reactions after injection of the COVID-19 vaccines, studies on side effects and severe allergic events have been ongoing worldwide. Now there are also first results on a successful premedication scheme and vaccination concepts for high-risk patients.
Eight COVID-19 vaccines are licensed in the Philippines. Severe reactions to these and anaphylactic events occur very rarely. But to react early, an interdisciplinary team set up a concept for different risk groups.
The number of allergic reactions requiring treatment has risen sharply in recent years. Among triggering medications, antibiotics play a major role in daily practice. Yet, there is still a need for better documentation.
Food allergies are rising but it is still unclear why. This is also reflected in guidelines for the prevention and treatment of food allergies. Risk factors are being discussed again.
CRSwNP usually accompanies those affected throughout their lives. Multiple surgeries and long-term steroid therapy are the standard treatment. This can be extended by biologics use.
Clear or almost clear skin and mild or no itch symptoms were top predictors of maintained response to tralokinumab in moderate-to-severe AD.